# Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Study · id `cardio:ct-nct04456803` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04456803](<https://clinicaltrials.gov/study/NCT04456803>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04456803

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 239 participants.

## Technical summary

Registry record NCT04456803. Randomized; no masking; primary purpose treatment. Start 2019-05-24 (actual); primary completion 2022-09-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 239 participants (enrolled count; ClinicalTrials.gov record NCT04456803, source copy `cardio:ctgov-nct04456803-2024-04-17`, retrieved 2026-10-26)
- Started: 2019-05-24 (actual) (ClinicalTrials.gov record NCT04456803, source copy `cardio:ctgov-nct04456803-2024-04-17`, retrieved 2026-10-26)
- Primary completion: 2022-09-13 (actual) (ClinicalTrials.gov record NCT04456803, source copy `cardio:ctgov-nct04456803-2024-04-17`, retrieved 2026-10-26)
- Completion: 2022-09-13 (actual) (ClinicalTrials.gov record NCT04456803, source copy `cardio:ctgov-nct04456803-2024-04-17`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04456803, source copy `cardio:ctgov-nct04456803-2024-04-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04456803-2024-04-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Condition: Hyperphosphatemia
- Condition: End Stage Renal Disease
- Condition: ESRD
- Intervention (Drug): Ferric citrate tablet
- Intervention (Drug): Sevelamer carbonate tablet
- Lead sponsor: Sinomune Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: e830bdb708fc74d7deaf38669827d87eb432f3bd1ec7d6ca025dd5e00e5ca327
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
